Drug Discovery – Page 16

Reproducibility issues in screening data during translational assessment – decision framework regulators expect

The first step in addressing reproducibility issues is recognizing the symptoms or signals that indicate potential deviations in data integrity during the translational phase. Typical signals may include:Click to read…

Lead candidate fails downstream criteria before IND-enabling studies – how to avoid late-stage attrition

The first step in addressing a failure of a lead candidate is observing the symptoms or signals that arise during the testing phases. These signals can manifest as unexpected results…

Poor hit-to-lead progression during early discovery – how to avoid late-stage attrition

Identifying symptoms related to poor hit-to-lead progression is the first step in the investigation process. Common signals include:Click to read the full article.

Lead candidate fails downstream criteria during regulatory interaction preparation – risk mitigation strategy

“`html Investigating Failures of Lead Candidates During Regulatory Preparation Advancing a lead candidate in drug discovery through regulatory preparation is a pivotal moment in the drug development lifecycle. When a…

ADME liabilities identified late during translational assessment – data package strengthening approach

When ADME liabilities are present, specific symptoms may arise during the drug development process. These signals often manifest in vitro or in vivo evaluation stages. Key indicators may include:Click to…

ADME liabilities identified late before IND-enabling studies – how to avoid late-stage attrition

Symptoms of ADME liabilities may manifest as unexpected results during in vitro and in vivo studies. Common indicators include:Click to read the full article.

ADME liabilities identified late during early discovery – data package strengthening approach

Identifying the signals that indicate ADME liabilities in early drug discovery is essential. These symptoms may range from lab results indicating poor solubility or high clearance rates to unexpected toxicity…

Target validation uncertainty during early discovery – data package strengthening approach

“`html Addressing Target Validation Uncertainty in Early Discovery: A Data Package Strengthening Approach In the current landscape of drug discovery, navigating the intricacies of target validation is paramount. As companies…

Reproducibility issues in screening data before IND-enabling studies – impact on IND success probability

Reproducibility issues can manifest in various ways during drug discovery. Here are key symptoms and signals to monitor closely:Click to read the full article.

Lead candidate fails downstream criteria during portfolio review – risk mitigation strategy

The first step in identifying issues with a lead candidate involves recognizing symptoms or signals that indicate potential failures in the review process. Common symptoms include:Click to read the full…

Lead candidate fails downstream criteria during portfolio review – how to avoid late-stage attrition

Identifying symptoms that signal potential issues with lead candidates requires keen observation and active monitoring. Common indicators include:Click to read the full article.

Lead candidate fails downstream criteria before IND-enabling studies – data package strengthening approach

The first step in addressing a lead candidate's failure is recognizing the symptoms or signals indicating that the candidate may not meet the required criteria for IND-enabling studies. These signs…